Analysts expect Fluidigm Co. (NASDAQ:FLDM) to report sales of $28.85 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Fluidigm’s earnings, with the highest sales estimate coming in at $29.74 million and the lowest estimate coming in at $28.00 million. Fluidigm posted sales of $28.96 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 0.4%. The company is expected to report its next earnings report after the market closes on Tuesday, November 5th.
On average, analysts expect that Fluidigm will report full year sales of $120.47 million for the current fiscal year, with estimates ranging from $120.20 million to $120.80 million. For the next year, analysts expect that the firm will report sales of $139.43 million, with estimates ranging from $135.60 million to $143.10 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Fluidigm.
Fluidigm (NASDAQ:FLDM) last announced its quarterly earnings results on Thursday, August 1st. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.08). Fluidigm had a negative return on equity of 31.45% and a negative net margin of 57.48%. The company had revenue of $28.20 million for the quarter, compared to the consensus estimate of $30.16 million. The company’s quarterly revenue was up 6.8% compared to the same quarter last year.
In other Fluidigm news, insider Levin Easterly Partners Llc sold 577,197 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $5.40, for a total value of $3,116,863.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Samuel D. Colella acquired 9,000 shares of Fluidigm stock in a transaction on Wednesday, August 7th. The stock was acquired at an average price of $7.00 per share, with a total value of $63,000.00. Following the purchase, the director now directly owns 115,481 shares in the company, valued at $808,367. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 15,000 shares of company stock valued at $95,460 and sold 1,238,708 shares valued at $9,517,533. 2.20% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in FLDM. New York State Common Retirement Fund grew its stake in Fluidigm by 28.9% in the 1st quarter. New York State Common Retirement Fund now owns 73,850 shares of the medical research company’s stock valued at $981,000 after purchasing an additional 16,550 shares during the period. Marshall Wace North America L.P. purchased a new position in shares of Fluidigm during the 1st quarter valued at $159,000. MetLife Investment Advisors LLC purchased a new position in shares of Fluidigm during the 1st quarter valued at $214,000. Metropolitan Life Insurance Co NY purchased a new position in shares of Fluidigm during the 1st quarter valued at $151,000. Finally, FMR LLC purchased a new position in shares of Fluidigm during the 1st quarter valued at $24,188,000.
Fluidigm stock traded up $0.42 during trading on Friday, hitting $4.73. 983,279 shares of the company were exchanged, compared to its average volume of 552,873. The business’s 50 day moving average is $5.03 and its 200 day moving average is $9.76. Fluidigm has a 52 week low of $4.03 and a 52 week high of $14.90. The company has a market capitalization of $299.13 million, a P/E ratio of -5.91 and a beta of 2.33. The company has a current ratio of 2.86, a quick ratio of 2.48 and a debt-to-equity ratio of 0.32.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Featured Article: What is Cost of Capital?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.